Science

May 2, 2025, 09:25

Myeloma Paper of the Day, May 2nd, suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: dFLC over 180 mg/L may no longer holds prognostic value in era of CyBorD/DaraCyBorD-based AL amyloidosis therapy and question utility of Mayo 2012 staging system in the era of highly effective chemo-immunotherapies.”

Title: Predictive Value of Free Light Chain Burden in Patients with AL Amyloidosis Treated with Bortezomib-Based Regimens

Authors: Brendan Saunders, Foteini Theodorakakou, Despina V Fotiou, Samuel Boullt, Benjamin Evans, Meletios Athanasios Dimopoulos, Efstathios Kastritis, Giada Bianchi.

You can read the Full Article on Blood Advances.

Myeloma Paper of the Day, May 2nd, suggested by Robert Orlowski

More posts featuring Robert Orlowski.

AL Amyloidosis Benjamin Evans Brendan Saunders cancer Despina V Fotiou Efstathios Kastritis Foteini Theodorakakou Giada Bianchi Meletios-Athanasios Dimopoulos Myeloma Paper of the Day OncoDaily Oncology Robert Orlowski Samuel Boullt

Vinay Prasad Rejoins FDA Days After Exit

New Paper Alert: Safety and Outcomes of T-DXd Retreatment After Grade 1 ILD Recovery

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2- Advanced Breast Cancer

Hubert Caron Retires from Roche-Genentech

Tyler Seibert: 10-year Results of FLAME Trial is Out Now